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SION: Resource use and cost increase as the severity of PD
worsens. The most signiﬁcant resource use increases occur when
patients reach HY4 due to mounting disability resulting in
increased hospitalisation and combination drug therapy.
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OBJECTIVES: Drug-induced parkinsonism (DIP) is an akinetic-
rigid syndrome induced by pharmacologic agents that can be dif-
ﬁcult to distinguished from idiopathic Parkinson’s disease (PD).
The medications potentially inducing parkinsonism include 
neuroleptic drugs, non-neuroleptic drugs, selective serotonin
reuptake inhibitors (SSRI), and catecholamine-depleting agents
(CDA). Here we examine the use of parkninsonism-inducing
drugs among Medicare beneﬁciaries and estimate the economic
burden of DIP. METHODS: We used the community-dwelling
population of 1992–2000 Medicare Current Beneﬁciary Survey
(MCBS) participants (97,999 subject-years). Bivariate compar-
isons were used to determine differences in the use of PD-
inducing drugs between the beneﬁciaries with and without 
PD. Using multivariate model, we estimated the effect of PD-
inducing drug use on the total medical expenditures. RESULTS:
Among all MCBS beneﬁciaries, 1.63% reported having PD,
8.31% used PD-inducing drugs, and 0.93% used both anti-PD
and PD-inducing drugs in a given year. Neuroleptic drugs were
the most commonly used drugs inducing PD (53.82%), followed
by the SSRI (41.45%), non-neuroleptic drugs (15.27%), and
CDA (2.23%). More people with self-reported PD used PD-
inducing drugs than people without PD (14.11% vs. 8.21%, p
< 0.001). Among beneﬁciaries using both anti-PD and DIP drugs,
65.63% used neuroleptic medications (83.21% for people not
taking anti-PD medications, p < 0.001), 30.00% used non-
neuroleptic drugs (13.28%, p < 0.001), and 35.16% used SSRI
(18.59%, p < 0.001). After adjusting for personal characteristics
and comorbidities, the total annual medical costs were signiﬁ-
cantly higher in PD patients with psychiatric problems who were
using neuroleptic drugs compared to other beneﬁciaries with 
psychiatric problems ($12109 vs. $10032, p < 0.001). CON-
CLUSIONS: More patients with self-reported PD are taking
medications known to potentially cause DIP compared to
Medicare beneﬁciaries without PD. The neuroleptic medications
are the most common PD-inducing drugs among elderly.
Although more research is needed, it is likely that DIP medica-
tions are contributing to the economic and health burden of
parkinsonism in Medicare beneﬁciaries.
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OBJECTIVES: To establish and analyse treatment satisfaction
and principal causes which result in termination of drug treat-
ment of Parkinson’s Disease (PD) in Russia. METHODS: The
retrospective analysis was carried out for treatment which
patients received. In the analysis, 241 patients with PD (male:
127, female: 114; mean age: 66.1 ± 7.5 years, duration of
disease: 5.2 ± 3.2 years) have been included. RESULTS: Major-
ity of patients received two or three drugs; 160 patients accepted
levodopa (mean dose: 612.0 ± 327.7mg daily); 105 patients
accepted anticholinergics such as trihexyphenidyl (mean dose:
5.0 ± 2.0mg); 83 patients accepted amantadine (mean dose:
253.9 ± 72.1mg); 41 patients accepted dopamine agonist such
as pramipexole (mean dose: 2.4 ± 1.0mg); and 35 patients
accepted selegiline (mean dose: 9.1 ± 3.2mg). Adverse events
resulted in termination of treatment more often for anticholin-
ergics (n = 32), less often for levodopa (n = 8), amantadine (n =
5) and pramipexole (n = 4). Insufﬁcient efﬁcacy was the most
often cause of end in treatment by trihexyphenidyl (n = 21),
selegiline (n = 17), amantadine (n = 15), and rare reason of end
of treatment by levodopa (n = 3), pramipexole (n = 2). High cost
of drugs was the most often reason of pramipexole (n = 27) can-
cellation and only one case led to cancellation of levodopa. In
other cases, patients were satisﬁed with the treatment. In Russia,
mean daily dose of levodopa costs about US$0.9, pramipexole—
US$3.96, selegiline—US$0.88, amantadine—US$0.05 and tri-
hexyphenidyl—US$0.02. CONCLUSIONS: Principal causes of
the termination of drug treatment of PD were adverse events,
insufﬁcient efﬁciency, and high cost. Reduction of cost of treat-
ment of dopamine agonists such as pramipexole could lead to
increase in number of PD patients who would continue to get
treated in Russia.
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OBJECTIVES: This retrospective study quantiﬁes the prevalence
of insomnia among patients with chronic obstructive pulmonary
disease (COPD) from a large outpatient database. COPD is an
umbrella term for the lung disease category associated with
airﬂow obstruction, which includes emphysema, chronic bron-
chitis, and chronic asthma, either alone or in combination.
METHODS: Data from April, 1996 to September, 2003 on
patients with a diagnosis of COPD (ICD-9 codes 491.2, 492.0,
492.8, 493.2, and 496) were extracted from the GE Medical
Systems database—a large, outpatient, multipractice electronic
database system with input from over 2000 practicing physicians
in 26 US states. The insomnia cohort was deﬁned as patients
having either a diagnosis consistent with insomnia (ICD-9 codes
307.4x [x = 1–2, 9] and 780.5x [x = 0, 2] or a prescription for
insomnia medication. Demographic characteristics, comorbid
conditions, and concomitant medications were evaluated.
RESULTS: A total of 5,777 (21.4%) of 27,052 patients in the
COPD cohort were identiﬁed as having a diagnosis and/or being
treated for insomnia, compared with 7.2% of the non-COPD
patients. CONCLUSIONS: This exploratory analysis revealed
that patients with COPD in this large outpatient database were
diagnosed with and/or treated for insomnia almost three times
as frequently as those patients not having a diagnosis of COPD.
These data suggest that insomnia is a common and clinically
important comorbidity associated with COPD. The nature of
this association should be further investigated with a well-
designed prospective study, and treatments for insomnia related
to COPD need to be examined in greater detail.
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